Last edition
News about "Soren Tullin"
Variant Bio partners with Boehringer Ingelheim for Research on Kidney Disease
The multi-year collaboration with Boehringer Ingelheim will leverage Variant Bio’s AI-powered Inference platform to identify novel kidney disease drug targets, with financial terms including upfront, licence and milestone payments that could exceed USD 120 million.
Soren Tullin | 08/01/2026 | By News Bureau | 164
Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class CKD Treatments
The collaboration will focus on accelerating the development of first-in-class oral small-molecule therapies for chronic kidney disease and other conditions, leveraging Rectify’s ABCC6-targeting platform designed to reduce pathological calcification.
Soren Tullin | 23/12/2025 | By News Bureau | 106
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy